You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
翰宇藥業(300199.SZ):生產的GLP-1原料藥2.19億元出口訂單已經進入陸續履約發貨階段
格隆匯 02-19 15:17

格隆匯2月19日丨翰宇藥業(300199.SZ)在互動平台表示,根據世界肥胖聯盟發佈的最新報吿《World Obesity Atlas 2023》數據顯示,全球超重/肥胖率將從2020年的38%增加至2035年的51%。日益擴大的未滿足市場需求,將對我司全球市場增長產生積極影響。截至目前,在中國,翰宇藥業的司美格魯肽注射液減肥適應症已於2024年2月1日獲得臨牀試驗申請受理通知書;在海外,翰宇藥業生產的GLP-1原料藥2.19億元出口訂單已經進入陸續履約發貨階段;GLP-1利拉魯肽製劑分別於2023年11月、2024年2月收穫了來自美國同一合作藥企的合計1.75億元商業批採購訂單,且公司利拉魯肽原料藥已經完成了DMF review cycle審評期並於2024年2月順利獲得了美國FDA“無進一步缺陷”的反饋結果,該結果對我司申報美國GLP-1利拉魯肽製劑ADNA上市獲批有積極促進作用。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account